Clinical value of serum squamous cell carcinoma antigen levels in predicting chemosensitivity, lymph node metastasis, and prognosis in patients with cervical squamous cell carcinoma

Table 4 Correlation analysis of SCC antigen levels with overall survival of patients with cervical squamous cell carcinoma

Variable	Mean survival times (months)	χ²	P
SCC antigen levels before chemotherapy		0.095	0.758
NACT group (n = 63)	40.16 (37.24, 43.07)
Conventional group (n = 39)	33.43 (31.31, 35.56)
NACT group		0.098	0.754
Chemotherapy-insensitive group (n = 32)	41.19 (37.29, 45.08)
Chemotherapy-sensitive group (n = 31)	39.25 (35.01, 43.50)
SCC antigen levels in NACT group before chemotherapy		9.880	0.002
< 4.55 (n = 29)	NA ^a
≥ 4.55 (n = 34)	NA ^a
SCC antigen levels ≥4.55 before chemotherapy		4.176	0.041
NACT group (n = 34)	36.40 (31.59, 41.22)
Conventional group (n = 21)	32.95 (30.95, 34.96)
SCC antigen levels in NACT group after the first chemotherapy		10.869	0.001
< 2.70 (n = 39)	43.75 (42.07, 45.43)
≥ 2.70 (n = 24)	34.40 (28.99, 40.81)

^a, in NACT group before chemotherapy, when SCC antigen levels < 4.55 ng/mL, 29 patients were survival and it is impossible to calculate the survival times of patients

ISSN: 1471-2407